MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises

被引:36
|
作者
Cortinovis, D. [1 ]
Monica, V. [2 ]
Pietrantonio, F. [3 ]
Ceresoli, G. L. [4 ]
La Spina, C. M. [4 ]
Wannesson, L. [5 ]
机构
[1] San Gerardo Hosp, Oncol Unit, Monza, Italy
[2] Univ Turin, San Luigi Hosp, Dept Oncol, Orbassano, Italy
[3] Ist Nazl Studio & Cura Tumori, Oncol Unit, I-20133 Milan, Italy
[4] Clin Humanitas Gavazzeni, Oncol Unit, Bergamo, Italy
[5] Oncol Inst Southern Switzerland, Bellinzona, Switzerland
关键词
miRNA; prognostic; predictive; therapy; NSCLC; SMALL RNAS; ADJUVANT CHEMOTHERAPY; ADENOCARCINOMA CELLS; EXPRESSION SIGNATURE; REDUCED EXPRESSION; PREDICTS SURVIVAL; RESISTANCE; DIAGNOSIS; DOCETAXEL; PROGNOSIS;
D O I
10.2174/13816128113196660755
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A biological characterization of tumor tissue is mandatory in NSCLC patients to identify cases at high risk of recurrence and to drive current targeted therapies such as EGFR and ALK inhibitors. In addition, promising results have been reported on the utility of molecular parameters for the prediction of the efficacy of systemic cytotoxic therapy. MicroRNAs ( miRNAs) are small single stranded non-coding RNA molecules, which regulate gene expression at the posttranscriptional level. Growing evidence suggests that miRNAs are expressed aberrantly in many human cancers and that they play a significant role in carcinogenesis and cancer progression. There is increasing evidence that miRNA profiling may become an accurate way to differentiate tumor subtypes, determine prognosis and response to therapy. This review aims to summarize the current literature on this rapidly evolving field.
引用
收藏
页码:3982 / 3990
页数:9
相关论文
共 50 条
  • [41] Immunotherapy in non-small cell lung cancer: current status, advances and challenges
    Tartarone, Alfredo
    Lerose, Rosa
    Tartarone, Marina
    MINERVA RESPIRATORY MEDICINE, 2024, 63 (03): : 110 - 120
  • [42] Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
    Garg, Pankaj
    Singhal, Sulabh
    Kulkarni, Prakash
    Horne, David
    Malhotra, Jyoti
    Salgia, Ravi
    Singhal, Sharad S.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (14)
  • [43] Adjuvant Therapy in Non-Small Cell Lung Cancer: Current and Future Directions
    Sangha, Randeep
    Price, Julie
    Butts, Charles A.
    ONCOLOGIST, 2010, 15 (08): : 862 - 872
  • [44] Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
    Duchemann, Boris
    Remon, Jordi
    Naigeon, Marie
    Cassard, Lydie
    Jouniaux, Jean Mehdi
    Boselli, Lisa
    Grivel, Jonathan
    Auclin, Edouard
    Desnoyer, Aude
    Besse, Benjamin
    Chaput, Nathalie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (06) : 2937 - 2954
  • [45] Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
    Lim, Sun Min
    Hong, Min Hee
    Kim, Hye Ryun
    IMMUNE NETWORK, 2020, 20 (01)
  • [46] Targeting glycolysis in non-small cell lung cancer: Promises and challenges
    Xu, Jia-Qi
    Fu, Yan-Li
    Zhang, Jing
    Zhang, Kai-Yu
    Ma, Jie
    Tang, Jing-Yi
    Zhang, Zhi-Wei
    Zhou, Zhong-Yan
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [47] Therapeutic vaccines in non-small cell lung cancer
    Socola, Francisco
    Scherfenberg, Naomi
    Raez, Luis E.
    IMMUNOTARGETS AND THERAPY, 2013, 2 : 115 - 124
  • [48] Therapeutic advances in non-small cell lung cancer
    Vallieres, Eric
    Peters, Solange
    Van Houtte, Paul
    Dalal, Paras
    Lim, Eric
    THORAX, 2012, 67 (12) : 1097 - 1101
  • [49] Current status and future perspective for oncogene analysis and molecular target therapy in non-small cell lung cancer
    Takahashi, Kazuhisa
    GENES & GENETIC SYSTEMS, 2016, 91 (06) : 319 - 319
  • [50] Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives
    Zukin, Mauro
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2012, 58 (02): : 263 - 268